Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A(C)VPpred: Transfer Learning-Enhanced Prediction of Antiviral and Anticoronavirus Peptides from Sequence Data.

Journal of chemical information and modeling·2026
Same author

Design of permeability-optimized target-binding macrocycles <i>via</i> direct preference optimization.

Chemical science·2026
Same author

Bridging Generative AI and Diffusion Models With Molecular Simulation to Design Anti-Quorum-Sensing De novo Peptides Targeting LasR of Pseudomonas aeruginosa.

Probiotics and antimicrobial proteins·2026
Same author

Prosta-omics: machine learning-driven TPSA prediction and molecular modeling of ASPM-inhibitors for prostate cancer treatment.

Molecular diversity·2026
Same author

Correction: Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia.

Scientific reports·2026
Same author

WGX-50 Promotes Healthy Ageing in Caenorhabditis elegans: A Combined Computational and Experimental Study.

Chemical biology & drug design·2025

Related Experiment Video

Updated: Jul 18, 2026

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

Progress in computational approach to drug development against SARS.

Kuo-Chen Chou1, Dong-Qing Wei, Qi-Shi Du

  • 1Gordon Life Science Institute, 13784 Torrey Del Mar Drive, San Diego, CA 92130, USA. kchou@san.rr.com

Current Medicinal Chemistry
|December 16, 2006
PubMed
Summary

Computer-aided drug discovery advances have identified promising SARS-CoV therapies. Computational methods highlight potential drug candidates and octapeptides for inhibiting the severe acute respiratory syndrome (SARS) enzyme.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jul 18, 2026

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Area of Science:

  • Computational chemistry
  • Bioinformatics
  • Drug discovery

Background:

  • The severe acute respiratory syndrome (SARS) outbreak in 2002 spurred research into effective therapies.
  • Significant progress has been made in developing drugs for SARS treatment.

Purpose of the Study:

  • To review advances in computer-aided drug discovery for SARS therapy.
  • To highlight computational approaches and potential therapeutic agents.

Main Methods:

  • Structural bioinformatics
  • Pharmacophore modeling
  • Molecular docking
  • Peptide-cleavage site prediction
  • Computational analysis

Main Results:

  • Identified specific compounds (C28H34O4N7Cl, C21H36O5N6) and KZ7088 as potential SARS drug candidates.
  • Highlighted octapeptides (ATLQAIAS, ATLQAENV, AVLQSGFR) as potential SARS enzyme inhibitors.
  • Elucidated methods for modifying octapeptides using "distorted key" theory for enhanced potency.

Conclusions:

  • Computer-aided drug discovery offers promising avenues for SARS therapy development.
  • Specific compounds and modified peptides show potential as SARS inhibitors.
  • Computational tools can aid in rapid diagnosis of SARS coronavirus.